DR-318 The causes and consequences of structural variations in cancer
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-318 The causes and consequences of structural variations in cancer
Structural variations (SVs) are large scale changes of DNA, which include deletions, duplications, inversion, translocations and other more complex forms. …
DR-315 Immune Surveillance in Metastases
The immune system constrains tumour growth. Cancer cells harbouring the capacity to evade the immune system are therefore selected. However, …
DR-313 Oncogenic pathways and their interaction with the immune system: prediction for response to combined therapies
We hypothesize that (in)activation of specific oncogenic pathways modulates the immune response to the tumor and initiates oncogenic pathway-specific immune …
DR-281 Identification of Cancer-Driving Mutations in Non-coding Regions
98% of our genome is non-coding and recent studies – including the landmark PCAWG analysis of 2,600 whole genomes – …
DR-307 The prevalence of homologous recombination deficiency (HRD) in sarcoma and its role as biomarker for PARP-inhibitor therapy
Soft tissue sarcoma treatment options are limited and prognosis is generally poor. It was recently shown that both osteosarcoma and …
DR-311 Whole Genome Sequencing for exploratory investigation of actionable mutations in AYA patients
Cancer in Adolescents and Young Adults (AYA, 18-39 years) differs potentially from other age groups in that AYA patients can …
DR-303 EP300/CREBBP mutations and MYB/MYC alteratations in cancer and their co-occurrence
Mutations in EP300/CREBBP and alterations in MYB and MYC are not uncommon in cancer. However, we do not know how often …
DR-269 Investigating the Role of EMT-mediated Immunotherapy Resistance
The cellular process of epithelial-to-mesenchymal transition (EMT) facilitates the spread of tumors (metastasis) and is involved in therapy resistance, however …
DR-284 Somatic mutations in non-coding RNA genes associated with cancer pathways
We wish to study the non-coding RNA genes and their somatic mutations in cancer. We have analysed the somatic mutations …
DR-196 Clinical and Genomic landscape of Carcinoma of Unknown Primary in the Netherlands, compared to metastasised known primary tumours
Patients with carcinoma of unknown primary (CUP) are patients with proven metastases but no primary tumour found. These patients have …
DR-271 Population genomics study to uncover the role of rare variants in heritable risk of sarcoma
Sarcoma is a rare and complex cancer with poor prognosis and survival. While existing genetic studies in cancer have focused on …
DR-197 In-depth molecular characterization of liver metastases from BC patients
One out of 8 women will develop breast cancer (BC) in her lifetime and BC remains the main cause of …
Kanker ontstaat door mutaties in het DNA. Er zijn steeds meer geneesmiddelen die werkzaam zijn bij specifieke fouten in het DNA van de tumor van een individuele patiënt. Een medicijn dat niet past als een sleutel in het slot werkt niet, terwijl je wel het risico van de bijwerkingen hebt.